Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Oct 3;30(10):1678-1685.
doi: 10.1093/ibd/izad307.

Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics

Ruben J Colman  1   2   3 , Stephanie A Vuijk  4 , Ron A A Mathôt  5 , Johan Van Limbergen  6   7 , Maria M E Jongsma  4 , Marco W J Schreurs  8 , Phillip Minar  3   9 , Lissy de Ridder  4 , Geert R A M D'Haens  2
Affiliations
Comparative Study

Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics

Ruben J Colman et al. Inflamm Bowel Dis. .

Abstract

Background: The use of concomitant azathioprine may improve efficacy and pharmacokinetic (PK) properties of infliximab (IFX) but is also associated with an increased risk of adverse events. Proactive therapeutic drug monitoring (pTDM) of IFX monotherapy is an alternative strategy to improve PK. The aim of this study was to evaluate whether IFX with an immunomodulator (combo) has PK benefits over IFX-pTDM (mono) in pediatric Crohn's disease (CD).

Methods: This PK analysis included pediatric CD patients who started either IFX combo (TISKids study) or IFX mono with pTDM (REFINE cohort). Combo and mono IFX trough levels (TLs) and antibodies-to-infliximab were assessed at infusion 3, 4, and 5. A population PK model was built to compare IFX PK outcomes (clearance [CL], TLs and cumulative exposure) between combo and mono groups at infusion 4 and 5. Clinical response and steroid-free clinical remission (SFCR) was assessed at infusion 4 and 5.

Results: This study included 128 pediatric CD patients (66 mono and 62 combo). At infusion 5, there was no significant difference between mono and combo median TLs 4.1 µg/mL (2.1, 7.8) vs 5.9 µg/mL (3.2, 9.4; P = .14) or median CL 0.26 L/d (0.21, 0.32) vs 0.26 L/d (0.21, 0.33; P = .81). Mono patients had a lower SFCR rate at infusion 5 (53% [31 of 59] vs 80% [32 of 40]; P = .01). Clinical response rates were significantly higher among combo than mono patients at both infusion 4 and 5.

Conclusions: This study suggests that there are no PK differences (TLs and CL) between combo and mono therapy in pediatric CD patients who started IFX.

Keywords: anti-TNF therapy; children; immunomodulator; inflammatory bowel disease; pharmacokinetics.

Plain language summary

This study compared the pharmacokinetics of infliximab combination therapy with azathioprine vs infliximab with proactive therapeutic drug monitoring as monotherapy among pediatric patients with Crohn’s disease within the first 22 weeks. No pharmacokinetic differences were found between monotherapy and combination therapy.

PubMed Disclaimer

Conflict of interest statement

L.R.: Collaboration with Abbvie, Lilly, Takeda, Janssen, and Pfizer. R.A.A.M. has received grants from governmental and societal research institutes such as NWO, ZonMW, Dutch Kidney Foundation, and Innovation Fund and unrestricted investigator research grants from Baxter/Baxalta/Shire/Takeda, Bayer, CSL Behring, Sobi, and CelltrionHC. He has served as advisor for Bayer, CSL Behring, Merck Sharp & Dohme, Baxter/Baxalta/Shire/Takeda. All grants and fees paid to the institution. R.C., S.V., J.vL., M.J., M.S., P.M., and G.H. have nothing to disclose.

Figures

Figure 1.
Figure 1.
Distribution of weight (kg) vs clearance (L/day/kg) demonstrates that lower weight is associated with higher clearance.
Figure 2.
Figure 2.
No difference between mono and combo therapy in median trough levels (μg/mL) (A) at infusion 4 and (B) infusion 5 or clearance (L/d) at (C) infusion 4 and (D) infusion 5.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hyams J, Crandall W, Kugathasan S, et al. ; REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132(3):863-73; quiz 1165-6. - PubMed
    1. van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2021;15(2):171-194. - PubMed
    1. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33(7):946-964. - PubMed
    1. Colman RJ, Xiong Y, Mizuno T, et al. Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2022;55(5):593-603. - PMC - PubMed
    1. Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe Ulcerative colitis. Gastroenterology. 2015;149(2):350-5.e2. - PubMed

Publication types

MeSH terms

Supplementary concepts